Stock DNA
Pharmaceuticals & Biotechnology
USD 1,136 Million (Small Cap)
NA (Loss Making)
NA
0.00%
-0.86
-999,999.00%
3.94
Revenue and Profits:
Net Sales:
29 Million
(Quarterly Results - Apr 2026)
Net Profit:
-39 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
34.68%
0%
34.68%
6 Months
3.85%
0%
3.85%
1 Year
95.25%
0%
95.25%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Kestra Medical Technologies Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
180.00%
EBIT Growth (5y)
-17.71%
EBIT to Interest (avg)
0
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0
Sales to Capital Employed (avg)
0
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
3.94
EV to EBIT
-6.18
EV to EBITDA
-6.55
EV to Capital Employed
22.78
EV to Sales
10.59
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-368.81%
ROE (Latest)
-50.76%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
RSI
No Signal
Bollinger Bands
Mildly Bearish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Apr 2026
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 32 Schemes (35.03%)
Foreign Institutions
Held by 45 Foreign Institutions (8.52%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Apr'26 - QoQ
Apr'26
Jan'26
Change(%)
Net Sales
28.60
24.60
16.26%
Operating Profit (PBDIT) excl Other Income
-37.00
-32.80
-12.80%
Interest
1.80
1.90
-5.26%
Exceptional Items
-0.40
0.20
-300.00%
Consolidate Net Profit
-38.80
-34.20
-13.45%
Operating Profit Margin (Excl OI)
-1,373.80%
-1,416.00%
4.22%
USD in Million.
Net Sales
QoQ Growth in quarter ended Apr 2026 is 16.26% vs 8.85% in Jan 2026
Consolidated Net Profit
QoQ Growth in quarter ended Apr 2026 is -13.45% vs -4.27% in Jan 2026
Annual Results Snapshot (Consolidated) - Apr'26
Apr'26
Apr'25
Change(%)
Net Sales
95.10
59.80
59.03%
Operating Profit (PBDIT) excl Other Income
-126.00
-98.40
-28.05%
Interest
7.50
7.70
-2.60%
Exceptional Items
-2.70
2.60
-203.85%
Consolidate Net Profit
-131.60
-113.80
-15.64%
Operating Profit Margin (Excl OI)
-1,416.40%
-1,778.50%
36.21%
USD in Million.
Net Sales
YoY Growth in year ended Apr 2026 is 59.03% vs 115.11% in Apr 2025
Consolidated Net Profit
YoY Growth in year ended Apr 2026 is -15.64% vs -20.94% in Apr 2025






